Bio-Rad Laboratories Inc (BIO-B) - Net Assets
Based on the latest financial reports, Bio-Rad Laboratories Inc (BIO-B) has net assets worth $7.13 Billion USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.21 Billion) and total liabilities ($3.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Bio-Rad Laboratories Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.13 Billion |
| % of Total Assets | 69.79% |
| Annual Growth Rate | 14.83% |
| 5-Year Change | -33.51% |
| 10-Year Change | 163.77% |
| Growth Volatility | 17.39 |
Bio-Rad Laboratories Inc - Net Assets Trend (1985–2024)
This chart illustrates how Bio-Rad Laboratories Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Bio-Rad Laboratories Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Bio-Rad Laboratories Inc (1985–2024)
The table below shows the annual net assets of Bio-Rad Laboratories Inc from 1985 to 2024. For live valuation and market cap data, see market cap of Bio-Rad Laboratories Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.57 Billion | -24.85% |
| 2023-12-31 | $8.74 Billion | -9.09% |
| 2022-12-31 | $9.62 Billion | -29.74% |
| 2021-12-31 | $13.69 Billion | +38.52% |
| 2020-12-31 | $9.88 Billion | +71.67% |
| 2019-12-31 | $5.76 Billion | +43.15% |
| 2018-12-31 | $4.02 Billion | +37.20% |
| 2017-12-31 | $2.93 Billion | +13.61% |
| 2016-12-31 | $2.58 Billion | +3.56% |
| 2015-12-31 | $2.49 Billion | +13.97% |
| 2014-12-31 | $2.19 Billion | -0.07% |
| 2013-12-31 | $2.19 Billion | +8.49% |
| 2012-12-31 | $2.02 Billion | +15.54% |
| 2011-12-31 | $1.74 Billion | +13.23% |
| 2010-12-31 | $1.54 Billion | +20.43% |
| 2009-12-31 | $1.28 Billion | +19.48% |
| 2008-12-31 | $1.07 Billion | +10.18% |
| 2007-12-31 | $971.69 Million | +18.57% |
| 2006-12-31 | $819.54 Million | +24.55% |
| 2005-12-31 | $657.97 Million | +10.23% |
| 2004-12-31 | $596.89 Million | +20.39% |
| 2003-12-31 | $495.81 Million | +29.42% |
| 2002-12-31 | $383.09 Million | +34.95% |
| 2001-12-31 | $283.88 Million | +16.05% |
| 2000-12-31 | $244.62 Million | +11.14% |
| 1999-12-31 | $220.10 Million | +2.71% |
| 1998-12-31 | $214.30 Million | +8.95% |
| 1997-12-31 | $196.70 Million | +7.19% |
| 1996-12-31 | $183.50 Million | +16.80% |
| 1995-12-31 | $157.10 Million | +21.03% |
| 1994-12-31 | $129.80 Million | +17.68% |
| 1993-12-31 | $110.30 Million | +2.99% |
| 1992-12-31 | $107.10 Million | +17.95% |
| 1991-12-31 | $90.80 Million | +11.96% |
| 1990-12-31 | $81.10 Million | +17.71% |
| 1989-12-31 | $68.90 Million | +15.80% |
| 1988-12-31 | $59.50 Million | +18.76% |
| 1987-12-31 | $50.10 Million | +15.70% |
| 1986-12-31 | $43.30 Million | +44.82% |
| 1985-12-31 | $29.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bio-Rad Laboratories Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 46252.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $7.42 Billion | 112.89% |
| Other Comprehensive Income | $-538.20 Million | -8.19% |
| Total Equity | $6.57 Billion | 100.00% |
Bio-Rad Laboratories Inc Competitors by Market Cap
The table below lists competitors of Bio-Rad Laboratories Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MD Pictures Tbk PT
JK:FILM
|
$1.52 Billion |
|
Acadia Healthcare Company Inc
NASDAQ:ACHC
|
$1.52 Billion |
|
Alexander & Baldwin Holdings Inc
NYSE:ALEX
|
$1.52 Billion |
|
EVEREST MED.LTD DL-0001
F:6HN
|
$1.52 Billion |
|
Yapp Automotive Systems Co Ltd
SHG:603013
|
$1.52 Billion |
|
COSMO Pharmaceuticals SA
SW:COPN
|
$1.52 Billion |
|
QCR Holdings Inc
NASDAQ:QCRH
|
$1.52 Billion |
|
Hyundai Green Food Co Ltd
KO:005440
|
$1.52 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bio-Rad Laboratories Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,741,200,000 to 6,569,300,000, a change of -2,171,900,000 (-24.8%).
- Net loss of 1,844,200,000 reduced equity.
- Share repurchases of 203,600,000 reduced equity.
- Other comprehensive income decreased equity by 202,200,000.
- Other factors increased equity by 78,100,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.84 Billion | -28.07% |
| Share Repurchases | $203.60 Million | -3.1% |
| Other Comprehensive Income | $-202.20 Million | -3.08% |
| Other Changes | $78.10 Million | +1.19% |
| Total Change | $- | -24.85% |
Book Value vs Market Value Analysis
This analysis compares Bio-Rad Laboratories Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 200.30x to 1.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $1.50 | $299.45 | x |
| 1986-12-31 | $1.99 | $299.45 | x |
| 1987-12-31 | $2.96 | $299.45 | x |
| 1988-12-31 | $2.60 | $299.45 | x |
| 1989-12-31 | $3.04 | $299.45 | x |
| 1990-12-31 | $3.45 | $299.45 | x |
| 1991-12-31 | $3.82 | $299.45 | x |
| 1992-12-31 | $4.50 | $299.45 | x |
| 1993-12-31 | $4.53 | $299.45 | x |
| 1994-12-31 | $5.35 | $299.45 | x |
| 1995-12-31 | $6.44 | $299.45 | x |
| 1996-12-31 | $7.35 | $299.45 | x |
| 1997-12-31 | $7.92 | $299.45 | x |
| 1998-12-31 | $8.67 | $299.45 | x |
| 1999-12-31 | $9.05 | $299.45 | x |
| 2000-12-31 | $9.96 | $299.45 | x |
| 2001-12-31 | $11.16 | $299.45 | x |
| 2002-12-31 | $14.73 | $299.45 | x |
| 2003-12-31 | $18.84 | $299.45 | x |
| 2004-12-31 | $22.53 | $299.45 | x |
| 2005-12-31 | $24.68 | $299.45 | x |
| 2006-12-31 | $30.41 | $299.45 | x |
| 2007-12-31 | $35.60 | $299.45 | x |
| 2008-12-31 | $37.67 | $299.45 | x |
| 2009-12-31 | $45.27 | $299.45 | x |
| 2010-12-31 | $54.59 | $299.45 | x |
| 2011-12-31 | $61.26 | $299.45 | x |
| 2012-12-31 | $70.35 | $299.45 | x |
| 2013-12-31 | $75.65 | $299.45 | x |
| 2014-12-31 | $75.01 | $299.45 | x |
| 2015-12-31 | $84.69 | $299.45 | x |
| 2016-12-31 | $87.00 | $299.45 | x |
| 2017-12-31 | $97.56 | $299.45 | x |
| 2018-12-31 | $133.00 | $299.45 | x |
| 2019-12-31 | $190.67 | $299.45 | x |
| 2020-12-31 | $327.58 | $299.45 | x |
| 2021-12-31 | $453.03 | $299.45 | x |
| 2022-12-31 | $322.82 | $299.45 | x |
| 2023-12-31 | $299.26 | $299.45 | x |
| 2024-12-31 | $232.84 | $299.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bio-Rad Laboratories Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -71.86%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.43x
- Recent ROE (-28.07%) is below the historical average (9.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 14.38% | 4.20% | 1.43x | 2.39x | $1.31 Million |
| 1986 | 14.09% | 4.82% | 1.25x | 2.35x | $1.77 Million |
| 1987 | 15.37% | 4.83% | 1.21x | 2.63x | $2.69 Million |
| 1988 | 15.97% | 4.78% | 1.28x | 2.61x | $3.55 Million |
| 1989 | 14.66% | 4.27% | 1.28x | 2.68x | $3.21 Million |
| 1990 | 13.19% | 3.73% | 1.34x | 2.63x | $2.59 Million |
| 1991 | 9.03% | 2.64% | 1.23x | 2.79x | $-880.00K |
| 1992 | 14.57% | 4.72% | 1.21x | 2.55x | $4.89 Million |
| 1993 | 2.54% | 0.85% | 1.26x | 2.36x | $-8.23 Million |
| 1994 | 12.02% | 4.39% | 1.35x | 2.03x | $2.62 Million |
| 1995 | 16.04% | 6.35% | 1.39x | 1.81x | $9.49 Million |
| 1996 | 14.28% | 6.26% | 1.47x | 1.55x | $7.85 Million |
| 1997 | 8.34% | 3.84% | 1.21x | 1.79x | $-3.27 Million |
| 1998 | 11.34% | 5.50% | 1.20x | 1.71x | $2.87 Million |
| 1999 | 5.32% | 2.13% | 0.82x | 3.04x | $-10.31 Million |
| 2000 | 12.71% | 4.28% | 1.12x | 2.64x | $6.64 Million |
| 2001 | 15.56% | 5.40% | 1.20x | 2.41x | $15.79 Million |
| 2002 | 17.71% | 7.60% | 1.24x | 1.88x | $29.55 Million |
| 2003 | 15.36% | 7.59% | 1.01x | 2.00x | $26.59 Million |
| 2004 | 11.43% | 6.26% | 0.79x | 2.30x | $8.55 Million |
| 2005 | 12.39% | 6.91% | 0.83x | 2.17x | $15.76 Million |
| 2006 | 12.60% | 8.11% | 0.80x | 1.95x | $21.31 Million |
| 2007 | 9.57% | 6.36% | 0.74x | 2.03x | $-4.17 Million |
| 2008 | 8.60% | 5.07% | 0.87x | 1.96x | $-14.60 Million |
| 2009 | 11.48% | 8.11% | 0.70x | 2.01x | $18.65 Million |
| 2010 | 12.07% | 9.63% | 0.63x | 1.99x | $31.82 Million |
| 2011 | 10.22% | 8.60% | 0.67x | 1.78x | $3.83 Million |
| 2012 | 8.40% | 8.18% | 0.60x | 1.71x | $-32.27 Million |
| 2013 | 3.56% | 3.65% | 0.63x | 1.55x | $-140.88 Million |
| 2014 | 4.07% | 4.08% | 0.65x | 1.53x | $-129.67 Million |
| 2015 | 4.54% | 5.60% | 0.54x | 1.49x | $-135.96 Million |
| 2016 | 1.09% | 1.36% | 0.54x | 1.49x | $-229.79 Million |
| 2017 | 3.92% | 5.31% | 0.51x | 1.46x | $-178.28 Million |
| 2018 | 8.98% | 15.76% | 0.41x | 1.40x | $-41.04 Million |
| 2019 | 30.56% | 76.08% | 0.29x | 1.39x | $1.18 Billion |
| 2020 | 38.61% | 149.83% | 0.20x | 1.31x | $2.83 Billion |
| 2021 | 31.09% | 145.57% | 0.16x | 1.30x | $2.89 Billion |
| 2022 | -37.73% | -129.45% | 0.21x | 1.40x | $-4.59 Billion |
| 2023 | -7.29% | -23.86% | 0.22x | 1.41x | $-1.51 Billion |
| 2024 | -28.07% | -71.86% | 0.27x | 1.43x | $-2.50 Billion |
Industry Comparison
This section compares Bio-Rad Laboratories Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,555,245,291
- Average return on equity (ROE) among peers: -57.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bio-Rad Laboratories Inc (BIO-B) | $7.13 Billion | 14.38% | 0.43x | $1.52 Billion |
| Abbott Laboratories (ABT) | $24.08 Billion | 18.37% | 0.83x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $1.47 Billion | -46.29% | 2.07x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $15.99 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.10 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $30.20 Million | 15.56% | 0.78x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $125.55 Million |
About Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biolog… Read more